hotspot -WSS

hotspot

author：fashion 2025-08-08 08:10:13 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Carbon Health diabetes program, a test of data

focus

WSS

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Weight loss drugs should be covered by insurers, AMA says

What would happen to your eyes if you looked at the solar eclipse?

Why drug prescriptions should include diagnoses

Why we need to separate burnout from moral injury in health care

Do masks work? RCTs can't tell us

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

What would happen to your eyes if you looked at the solar eclipse?

Psychedelics group wrestles with new pharma identity

The strategy behind pharma's lawsuits over drug pricing reform

Guidelines to prevent youth baseball injuries need more muscle

Type 2 diabetes prevention programs work at large scale: study

Dobbs anniversary: the lost opportunity of abortion as health care

Type 2 diabetes prevention programs work at large scale: study

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

focus

Healthy food access boosts outcomes in two studies

How state and local governments are sidelining science

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

STAT's guide to the next generation of CAR

Cloning humans is technically possible. It's curious no one has tried

Today's health inequities arise from racist U.S. history, say experts

hotspot

entertainment

focus

focus